Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 55Recurrence 6Lymphoma, Mantle-Cell 5Leukemia, Myeloid, Acute 5Waldenstrom Macroglobulinemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Immunoglobulin Light-chain Amyloidosis 4Neoplasms, Plasma Cell 3Lymphoma 3Plasmacytoma 2Neoplasms 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2Leukemia, Biphenotypic, Acute 2Carcinoma, Renal Cell 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Proteostasis Deficiencies 1Plasmablastic Lymphoma 1POEMS Syndrome 1Neurofibrosarcoma 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1

Interventions

Cytarabine 32Cyclophosphamide 16Busulfan 16fludarabine phosphate 14Peripheral Blood Stem Cell Transplantation 13Filgrastim 13Idarubicin 11Etoposide 11Antilymphocyte Serum 10Cyclosporine 9Mitoxantrone 8Radiotherapy 7Methotrexate 7Daunorubicin 7Whole-Body Irradiation 5Tacrolimus 5Cord Blood Stem Cell Transplantation 5Clofarabine 5Mycophenolic Acid 4Methylprednisolone 4Flow Cytometry 4Arsenic Trioxide 4aldesleukin 3Topotecan 3Thiotepa 3Melphalan 3Imatinib Mesylate 3Gemtuzumab 3Cytogenetic Analysis 3Cyclosporins 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Megakaryoblastic, Acute × ixazomib × Clear all
NCT02030405 2019-04-05

Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Stanford University

Phase 2 Terminated
4 enrolled 10 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡